Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats.
The aim of this study was to examine the role of endothelin-A (ET(A)) receptors in mediating the hypertension and renal injury associated with high salt intake in Dahl salt-sensitive (DS) rats. To achieve this goal, we examined the effects of chronic selective ET(A) antagonist (A-127722) treatment at a dose of 10 mg/kg/d on arterial pressure, renal function, and morphology in DS and Dahl salt-resistant (DR) rats placed on a high sodium (8% NaCl) diet (HSD) for 3 weeks. Placement of DS rats (n=13) on HSD for 3 weeks caused a progressive increase in systolic pressure (from 118+/-3 to 186+/-15 mm Hg). The increase in systolic pressure was significantly attenuated (from 125+/-4 to 167+/-12 mm Hg) in DS rats treated with A-127722 (n=13). Mean arterial pressure (MAP) measured directly at the end of the study was also significantly lower by 18 mm Hg (P<.02) in the DS rats treated with A-127722. The slope of the chronic pressure-natriuresis curve was shifted to the right in DS rats and to the left by chronic ET(A) receptor blockade in DS rats. The hypertension in DS rats was associated with marked proteinuria (from 4.1+/-1.1 to 74.3+/-5.3 mg/24 h/100 g body weight) that was significantly attenuated (from 5.7+/-1.2 to 55.2+/-6.5 mg/24 h/100 g body weight) in DS rats treated with A-127722. The percentage of glomeruli displaying fibrosis, hypercellularity, and hyalinization was also significantly reduced after treatment with A-127722 in DS rats. Arterial pressure, protein excretion, renal hemodynamics, and morphologic structure were not significantly changed in response to ET(A) receptor blockade in DR rats placed on HSD. These data indicate that endothelin-A receptor activation may play a role in the exacerbation of hypertension and development of renal injury in DS rats.
Kassab
S
S
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Miller
M T
MT
Novak
J
J
Reckelhoff
J
J
Clower
B
B
Granger
J P
JP
D000818:Animals; D000077868:Atrasentan; D001794:Blood Pressure / Q000187:drug effects*; D004039:Diet, Sodium-Restricted; D065128:Endothelin Receptor Antagonists; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006973:Hypertension / Q000235:genetics / Q000503:physiopathology* / Q000517:prevention & control*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D009318:Natriuresis; D011188:Potassium / Q000097:blood / Q000652:urine; D011507:Proteinuria; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D044022:Receptor, Endothelin A; D012039:Regional Blood Flow / Q000187:drug effects; D012964:Sodium / Q000097:blood / Q000652:urine; D012982:Sodium, Dietary; D013599:Systole / Q000187:drug effects
D065128:Endothelin Receptor Antagonists; D011759:Pyrrolidines; D044022:Receptor, Endothelin A; D012982:Sodium, Dietary; D012964:Sodium; D011188:Potassium; D000077868:Atrasentan